Affiliations: [a] Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA | [b] Scrips Clinic and Research Foundation, La Jolla, CA, USA | [c] University of California at San Diego, USA | [d] Abbott Biotech Inc., Needham Heights, MA, USA | [e] VA Medical Center, Birmingham, AL, USA
Note: [] Address reprint requests to Mansoor N. Saleh, M.D., University of Alabama at Birmingham, Comprehensive Cancer Center, L.B. Wallace Tumor Institute – 262H, UAB Station, Birmingham, AL 35294-3300, USA.
Note: [] ALY is supported by a grant from the Food and Drug Administration (FDR 000-377).
Abstract: The chimeric monoclonal anti-GD2 antibody ch14.18 is made up of the variable region of the murine anti-GD2 antibody 14.18 (or its IgG2a switch variant 14G2a) and the constant region of human IgG1k. Ch14.18 mediates antibody dependent cytoxicity and complement dependent lysis in vitro. In a phase 1 trial, 13 patients with metastatic melanoma received ch14.18 as a single dose of 5–100 mg. Therapy was associated with an infusion-related abdominal/pelvic pain syndrome, which required intravenous morphine for control. The pharmacokinetics of ch14.18 best fit a two-compartment model with a T1/2α of 24±1 hr and a T1/2β of 181±73 hr. Eight of 13 patients developed a weak-modest antibody response directed at the variable region of ch14.18. Clinical antitumor responses were not observed at the doses employed in this study. However, patients receiving >45 mg of ch14.18 had antibody detectable on tumor cells analyzed by fluorescent activated cell sorter. Further modification of the therapeutic regime employing larger doses and frequent administration of ch14.18 are planned.
